DRUG · Unmapped registry intervention
Zilovertamab vedotin
Find medicine records ·
Find other trials using this name
Clinical trial
A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)
NCT04504916
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedA Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)
Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Non-squamous Non-small-cell Lung Cancerunresolved
NSCLCverified · MONDO: non-small cell lung carcinoma
ER-negative Breast Cancerunresolved
PR-negative Breast Cancerunresolved
HER2-negative Breast Cancerunresolved
ER-positive Breast Cancerunresolved
PR-positive Breast Cancerunresolved
Platinum-resistant Ovarian Cancerunresolved
Gastric Cancerverified · MONDO: gastric cancer
Interventions
Sponsors & collaborators
Mapped research locations
MontrealQuebec, Canada2New YorkNew York, United States1HoustonTexas, United States1BostonMassachusetts, United States1TorontoOntario, Canada1San AntonioTexas, United States1SeattleWashington, United States1OrlandoFlorida, United States1VancouverBritish Columbia, Canada1EdmontonAlberta, Canada1QuébecQuebec, Canada1HollywoodFlorida, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04504916 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.